How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Authors
Keywords
Diabetes mellitus type 2, Empagliflozin, Vascular function, Central hemodynamics, Inflammation
Journal
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-29
DOI
10.1186/s12933-019-0839-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
- (2018) Concetta Irace et al. Cardiovascular Diabetology
- SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
- (2018) Dustin M. Lee et al. Cardiovascular Diabetology
- Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
- (2018) Sarayut Lahnwong et al. Cardiovascular Diabetology
- Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes
- (2018) Nobuhiro Tahara et al. Current Vascular Pharmacology
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- (2018) Annayya R. Aroor et al. Cardiovascular Diabetology
- Empagliflozin directly improves diastolic function in human heart failure
- (2018) Steffen Pabel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury
- (2017) Pongpan Tanajak et al. JOURNAL OF ENDOCRINOLOGY
- Diabetes: SGLT2 inhibitors and diabetic ketoacidosis — a growing concern
- (2017) Guillermo E. Umpierrez Nature Reviews Endocrinology
- Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
- (2017) Ioanna Andreadou et al. Frontiers in Physiology
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
- (2016) Nikolaus Marx et al. EUROPEAN HEART JOURNAL
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice
- (2016) Weiling Leng et al. MEDIATORS OF INFLAMMATION
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
- (2015) Michael Roden et al. Cardiovascular Diabetology
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension
- (2015) Christian Ott et al. EuroIntervention
- Comparison of an Oscillometric Method with Cardiac Magnetic Resonance for the Analysis of Aortic Pulse Wave Velocity
- (2015) Hans-Josef Feistritzer et al. PLoS One
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- Oscillometric estimation of aortic pulse wave velocity
- (2013) Bernhard Hametner et al. BLOOD PRESSURE MONITORING
- 2013 ESH/ESC Guidelines for the management of arterial hypertension
- (2013) Giuseppe Mancia et al. JOURNAL OF HYPERTENSION
- Wave Reflections, Assessed With a Novel Method for Pulse Wave Separation, Are Associated With End-Organ Damage and Clinical Outcomes
- (2012) Thomas Weber et al. HYPERTENSION
- Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study
- (2010) Mary J Roman et al. JOURNAL OF HYPERTENSION
- Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?
- (2009) Kang-Ling Wang et al. JOURNAL OF HYPERTENSION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now